2. Signaling Pathways
  3. Epigenetics
  4. Glycosyltransferase

Glycosyltransferase

Glycosyltransferases (GTs) are key enzymes in the biosynthesis of ginsenosides, which can catalyze the transfer of glycans from donor molecules to acceptor molecules, and form a variety of biologically active glycoside compounds.

Cat. No. Product Name Effect Purity Chemical Structure
  • HY-129389
    Benzyl-α-GalNAc
    		Inhibitor 99.93%
    Benzyl-α-GalNAc is a potent O-glycosylation inhibitor. Benzyl-α-GalNAc effectively inhibits the proliferation and activation of LX-2 cells and suppresses the expression of collagen I/III, which has good potential for investigation in liver fibrosis. Benzyl-α-GalNAc also significantly enhances the anti-tumour activity of 5-Fluorouracil (HY-90006) (e.g. pancreatic cancer) by inhibiting O-glycosylation.
    Benzyl-α-GalNAc
  • HY-116705
    2-Deoxy-2-fluoro-L-fucose
    		99.99%
    2-Deoxy-2-fluoro-L-fucose, an L-fucose analog, is a fucosylation inhibitor. 2-Deoxy-2-fluoro-L-fucose inhibits de novo synthesis of GDP-fucose in mammalian cells. Fucosylation is a relatively well-defined biomarker for progression in many human cancers; for example, pancreatic and hepatocellular carcinoma.
    2-Deoxy-2-fluoro-L-fucose
  • HY-W096600
    2F-Peracetyl-Fucose
    		Inhibitor 99.54%
    2F-Peracetyl-Fucose (1,3,4-Tri-O-acetyl-2-deoxy-2-fluoro-L-fucopyranos) acts as a potent fucosyltransferase (FUT) inhibitor.
    2F-Peracetyl-Fucose
  • HY-157646
    MZ-101
    		99.42%
    MZ-101 (GYS1-IN-2) is an orally active, potent and selective small-molecule glycogen synthase 1 (GYS1) inhibitor with with an IC50 value of 0.041 µM. MZ-101 reduces glycogen concentrations in cells and in mice. MZ-101 can used to study GYS1 -mediated Pompe disease and other glycogen storage diseases.
    MZ-101
  • HY-107366
    SGN-2FF
    		Inhibitor 98.0%
    SGN-2FF is a potent and orally active inhibitor of fucosylation, directly inhibits fucosyltransferase activity. SGN-2FF possesses antitumor activity.
    SGN-2FF
  • HY-E71155
    1,3-β-Oligoglucan phosphorylase
    1,3-β-Oligoglucan phosphorylase (EC 2.4.1.30) belongs to the family of glycosyltransferases, specifically the hexosyltransferases. The two substrates of this enzyme are (1,3-beta-D-glucosyl) n and phosphate, whereas its two products are (1,3-beta-D-glucosyl) n-1 and alpha-D-glucose 1-phosphate.
    1,3-β-Oligoglucan phosphorylase
  • HY-E71154
    1,3-β-Glucan synthase
    1,3-β-Glucan synthase (EC 2.4.1.34) belongs to the family of glycosyltransferases, specifically the hexosyltransferases.
    1,3-β-Glucan synthase
  • HY-E71206
    α,α-Trehalose phosphorylase
    α,α-Trehalose phosphorylase (EC 2.4.1.64) belongs to the family of glycosyltransferases, specifically the hexosyltransferases.
    α,α-Trehalose phosphorylase
  • HY-139056
    SU0268
    		Inhibitor 99.96%
    SU0268 is a potent and specific inhibitor of 8-Oxoguanine DNA glycosylase 1 (OGG1). SU0268 regulates inflammatory responses during Pseudomonas aeruginosa infection.
    SU0268
  • HY-125961
    T3Inh-1
    		Inhibitor 99.93%
    T3Inh-1 is a potent and selective inhibitor of ppGalNAc-T3 (IC50=7 μM). T3Inh-1 reduces FGF23 hormone levels in both tissue cells and mice, without causing any toxic side effects. T3Inh-1 also prevents breast cancer cells. The enzyme ppGalNAc-T3 is implicated in at least two medically important pathways: cancer metastasis and stabilization of FGF23 (regulates phosphate levels in the bloodstream).
    T3Inh-1
  • HY-115625
    AG-205
    		Inhibitor 99%
    AG-205 is a progesterone receptor membrane component 1 (PGRMC1) antagonist and CGT inhibitor, with an IC50 of 50 μM against rat CGT. AG-205 exhibits antimitotic, antimigratory and anti-invasive activities. AG-205 increases the expression of genes encoding cholesterol biosynthesis pathway or steroidogenic enzymes. AG-205 promotes the regulation of cell cycle by apoptosis and reduces the migratory and invasive capacities of ovarian and breast cancer cells. AG-205 can be used in research related to renal cancer and breast cancer.
    AG-205
  • HY-131062
    yGsy2p-IN-1
    		Inhibitor 98.57%
    yGsy2p-IN-1 is a potent inhibitor for yeast glycogen synthase 2 (yGsy2p). yGsy2p-IN-1 is a competitive human glycogen synthase 1 (hGYS1) inhibitor with an IC50 of 2.75 μM and a Ki of 1.31 μM for wild-type hGYS1. yGsy2p-IN-H23 a pyrazole inhibitor, is used for glycogen storage diseases (GSDs).
    yGsy2p-IN-1
  • HY-E70047
    alpha-1,4-Galactosyltransferase (LgtC)
    alpha-1,4-Galactosyltransferase (LgtC) (A4GALT) is a glycosphingolipid-specific glycosyltransferase. alpha-1,4-Galactosyltransferase (LgtC) transfers a galactose to the alpha-1,4 position of lactosylceramide to form globotriaosylceramide. alpha-1,4-Galactosyltransferase (LgtC) can be used for the synthesis of P1 blood group antigens.
    alpha-1,4-Galactosyltransferase (LgtC)
  • HY-120872
    AJS1669 free acid
    		Activator 99.15%
    AJS1669 free acid is a potent and orally available glycogen synthase (GS) activator. AJS1669 improves glucose metabolism and reduces body fat mass in mice[1].
    AJS1669 free acid
  • HY-163121
    PST3.1a
    		Inhibitor
    PST3.1a is an orally active and brain-penetrant N-acetylglucosamine glycosyltransferase (MGAT5) inhibitor with a human IC50 of 2 µM. PST3.1a inhibits TGFβR and FAK signaling pathway activity. PST3.1a alters β1,6-GlcNAc N-glycans and microtubule/microfilament integrity, increases OLIG2 expression, and inhibits proliferation, migration, invasiveness, and clonogenic capacities of glioblastoma initiating cells. PST3.1a reduces invasive and proliferative capacity of glioblastoma initiating cells in orthotopic graft models, increases overall survival of orthotopic graft model mice. PST3.1a blunts MGAT5 overexpression, decreases renal fibrosis via collagen 1, collagen 4, and galectin 3 downregulation in a rat chronic kidney disease model. PST3.1a can be used for the research of glioblastoma multiforme and chronic kidney disease.
    PST3.1a
  • HY-E70191
    β-1,4-Galactosyltransferase 2
    β-1,4-Galactosyltransferase 2 catal exclusive specificity for the donor substrate UDP-galactose and all transfer galactosein a beta1,4 linkage.
    β-1,4-Galactosyltransferase 2
  • HY-105495
    Iliparcil
    		Ligand 98.32%
    Iliparcil has a potent antithrombotic activity in the Wessler model in rats. Iliparcil has oral activity.
    Iliparcil
  • HY-E70138
    β-1,4-Galactosyltransferase 7
    β-1,4-Galactosyltransferase 7 has exclusive specificity for the donor substrate UDP-galactose and all transfer galactose in a β-1,4 linkage to similar acceptor sugars: GlcNAc, Glc, and Xyl..
    β-1,4-Galactosyltransferase 7
  • HY-E70044
    beta-1, 3-N-Acetylhexaminyltransferase (LgtA)
    beta-1, 3-N-Acetylhexaminyltransferase (LgtA) is a glycosyltransferase, is often used in biochemical studies. beta-1, 3-N-Acetylhexaminyltransferase (LgtA) catalyzes the transfer of N-acetylglucosamine from UDP-GlcNAc to N-acetyllactosamine and lactose.
    beta-1, 3-N-Acetylhexaminyltransferase (LgtA)
  • HY-N11424
    Bilirubin diglucuronide
    		Substrate
    Bilirubin diglucuronide is a bilirubin glycoside conjugate with a 1-O-acyl β-D-glucuronide structure. Bilirubin diglucuronide is the major conjugated bilirubin (HY-N0323) and predominant pigment excreted in the bile of adult humans, rats, dogs and cats. Bilirubin diglucuronide is mainly synthesized via UDP-glucuronosyltransferase-mediated transfer of glucuronic acid from UDP-glucuronic acid to bilirubin monoglucuronide, or via enzymatic disproportionation of two moles of bilirubin monoglucuronide (predominantly producing the IXα configuration). In addition, Bilirubin diglucuronide can also be synthesized from bilirubin or its monoglucuronide in a UDP-glucuronic acid-dependent manner. Pretreatment with phenobarbital significantly enhances the formation process of Bilirubin diglucuronide.
    Bilirubin diglucuronide
Cat. No. Product Name / Synonyms Application Reactivity